A novel consortium used as potent vaccine for treating of enteric fever, comprised of isolated Outer Membrane Vesicles (OMVs) taken from two different strains of typhoidal Salmonella species.

Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Disclosed is the use of foam compositions for the delivery of therapeutics to a body cavity, organ, or tissue of a patient in need thereof. Also disclosed are foam compositions, and devices for delivering the composition to a body cavity or the interior or exterior of an organ. Additionally, methods of treating cancer in the internal organs or the body cavity using the foam compositions are also disclosed.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.

The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention.

An immunogenic composition comprising a deletion mutant of a Clostridioides difficile TcdB toxin (such as TcdB2 or TcdB1) that lacks residues at least from amino acid residue 1769 to amino acid residue 1787 of a wild-type TcdB amino acid sequence or of a protein having high identity thereto, a vaccine comprising the immunogenic composition, a method of stimulating an immune response, a nucleic acid which encodes the amino acid sequence of the deletion mutant, a vector encoding the nucleic acid, and a host cell comprising the vector.

The present invention is directed to a method of treating poultry hatchlings in a hatchling tray. The method comprises of providing a soft gel form capable of being dispensed through a spray nozzle, providing a spray dispensing apparatus, the apparatus being capable of delivering a predetermined volume of the gel as a plurality of small beadlets through a plurality of nozzles, placing the hatchling tray containing the hatchlings beneath the nozzles of the dispensing apparatus, dispensing the predetermined volume of the soft gel containing the therapeutic agent as small beadlets into the hatchling tray and allowing the hatchlings to consume the beadlets. The present invention is also directed to a dispensing apparatus for dispensing a therapeutic agent in a soft gel into a hatchling tray of poultry hatchlings.

The present invention relates to the field of native outer membrane vesicles (nOMVs), particularly nOMVs having increased levels of lipoproteins on their surface and use of same in immunogenic compositions.

It has been established that bacterial hybrid vectors including prokaryote cells modified by the addition of cationic polymers to the outer surface of the cell can selectively deliver exogenous cargos, such as nucleic acids, polypeptides and small molecules to an eukaryotic cell, such as an antigen presenting cell. Compositions and methods for the delivery and expression of nucleic acids and polypeptides to eukaryotic cells are described. The bacterial hybrid vectors include one or more cationic polymers that enhance uptake by antigen presenting cells. The hybrid bacterial vectors include expression vectors that express one or more factors to enhance lysosomal escape and cytosolic delivery of cargo. The vectors are useful as adjuvants to stimulate and/or induce immune responses to any desired antigen, to develop a protective immune response in a subject.

The present invention provides vaccine or immunogenic compositions comprising novel antigens derived from the equine strain of influenza H3N8. These proteins and specific immunogenic domains are effective as primary universal influenza antigens. The disclosed vaccines or immunogenic compositions are highly effective in inducing HA specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes. In some embodiments, the vaccine is cross-protective against two or more (e.g., 2, 3, 4, 5, or 6) subtypes of influenza with or without the use of an adjuvant.